Catalent Pharma Solutions, a global provider of drug delivery technologies and development solutions, is expanding its operations in Madison, Wisconsin. The $34 million project is expected to create more than 100 new jobs.
The company will add more than 22,000 square feet at its existing facility on Madison’s west side to increase manufacturing, office and laboratory space. The project is expected to begin in November, will double the size of the company’s workforce in Madison.
“Our Madison facility is an important part of Catalent’s development capability, and serves a market for biologically derived drugs that is outstripping that of small molecule drugs,” said John Chiminski, Catalent’s President/CEO. “Together with our GPEx cell line technology and SMARTag antibody-drug conjugation chemistry, our partners continue to benefit from a compelling and differentiated portfolio of biologics capabilities.”
To help secure the company’s commitment, the Wisconsin Economic Development Corporation (WEDC) awarded Catalent with up to $1 million in state tax credits over the next three years. The actual amount of credits the company will receive is contingent upon the level of capital investment in Madison during the three-year period.
“Catalent has operations throughout the world and had other options for its expansion plans. I want to thank the company for its continued to commitment to Wisconsin by deciding to grow here,” said Lt. Governor Rebecca Kleefisch, who joined company officials at a groundbreaking ceremony today. “This expansion will further enhance the Madison region’s leadership position in the pharmaceutical and health industries.”
“WEDC is pleased to assist Catalent as it continues to expand in Madison,” said Mark Hogan, Secretary/CEO of WEDC, the state’s lead economic development organization. “Catalent is one of the many companies deciding to grow here because of the state’s strong business climate, outstanding workforce and world-class university system.”